Analysis:

(a) Source analysis:

**Web articles:**
1. Robinhood (2026-02-07): Real-time stock data showing TRMB at $66.67 with 94% positive analyst ratings. Factual data source, dated exactly on the baseline date. High quality for price reference.

2. CNN Markets (undated, but recent): Shows TRMB at $66.15 closing, up 3.39%. Reports Q3 earnings beat and flat revenue. Factual financial data with minimal opinion. High quality.

3. TradingView (undated): Aggregates 12 analysts with mean price target $98.08 and "Strong Buy" rating. Mix of facts (price targets) and aggregated opinions. Moderate quality - opinions are from identifiable analysts.

4. Motley Fool (2026-01-03): Opinion piece arguing TRMB undervalued by 30%. Author Lee Samaha's bullish thesis based on FCF projections. Heavy opinion with some factual FCF data. Lower weight given to advocacy stance.

5. Barchart (2026-02-05): Reports TRMB down 13.5% over 52 weeks, Q3 beat, raised guidance. 13 analysts with "Strong Buy" consensus and mean target $96.09. Factual earnings data and identifiable analyst aggregation. High quality.

6. Stock Titan (2025-12-05): Reports $1B buyback authorization. Factual corporate action. High quality for this specific data point.

**Asknews articles:**
7. Multiple Stockpulse articles (Feb 4-6, 2026): Show TRMB declining -4.8% on Feb 4 to ~$64.62, then -1.63% on Feb 5 to $63.98. These are factual price movements immediately before the baseline date. Critical high-quality data.

8. Barchart article (Feb 5, 2026): Duplicate of earlier source, confirms analyst consensus.

9. Defense World (Feb 4, 2026): Reports Rep. Delaney sold TRMB shares on Jan 28. Minor insider selling. Factual but weak signal.

10. GuruFocus articles (Jan 16-Feb 3, 2026): Track daily declines of -4.06%, -3.48%, -4.6% on various dates in late January/early February. Shows clear downward momentum. Factual price data, high quality for trend analysis.

11. Benzinga (Dec 16, 2025): Keybanc upgraded TRMB from Sector Weight to Overweight with $99 target. Identifiable analyst opinion. Moderate quality but dated.

**Key factual findings:**
- TRMB closed Feb 7 at $66.67 (per Robinhood) or $63.98-$66.15 range (per various sources)
- Sharp decline of ~20% since end of January 2026
- Multiple days of 3-5% drops in late Jan/early Feb
- Earnings scheduled Feb 10, 2026 (between baseline and outcome dates)
- Strong analyst consensus ($96-98 targets, "Strong Buy" ratings)
- Recent institutional selling pressure evident

(b) Evidence analysis:

**Strong evidence:**
- **Recent price momentum strongly negative**: Multiple independent sources (GuruFocus, Stockpulse) document 4-5% daily declines on Jan 16, 20, 29, Feb 3, 4. This represents a clear breakdown from $78+ to $64-66 range in just 2 weeks. Historical patterns show momentum often persists over 5-day windows.
- **Earnings catalyst on Feb 10**: Positioned mid-window between Feb 7-14. Earnings announcements typically drive 3-8% moves in either direction for mid-cap stocks. This is a structural factor that makes the 5-day period non-typical.

**Moderate evidence:**
- **Institutional selling**: Swiss bank sold substantial block, insider sales by Rep. Delaney (though small). Suggests negative near-term sentiment from informed actors.
- **$1B buyback authorization**: Could provide price support, but execution timing uncertain and hasn't prevented recent 20% decline.
- **Analyst upgrades**: Keybanc, Barclays upgraded in Dec-Jan with $99-101 targets. However, price action suggests market disagreeing with analysts in near-term.

**Weak evidence:**
- **52-week positioning**: Trading near middle of range. Provides no directional signal.
- **Broader market context**: No information on S&P 500 or sector trends for Feb 7-14 period.

(c) Timeframe analysis:

Prediction timeframe: 5 trading days (Feb 7 → Feb 14, 2026)

**Critical timing factor**: Earnings release on Feb 10 falls on Day 3 of the 5-day window. This fundamentally changes the probability distribution:
- Days 1-2 (Feb 7-10): Pre-earnings drift, typically modest moves
- Day 3 (Feb 10): Earnings reaction, typically 3-8% move
- Days 4-5 (Feb 11-14): Post-earnings digestion

If timeframe were halved (2-3 days): Would likely miss earnings catalyst entirely, reverting closer to base rate ~53% with downward momentum bias → ~45-48%.

If timeframe were doubled (10 days): Would include full earnings reaction plus additional time for trend reversal, potentially increasing probability if earnings beat expectations → ~55-60%.

The 5-day window is uniquely positioned to capture the earnings volatility, which dominates the forecast.

(d) Justification for shifts from 53% base rate:

**Downward pressures (-8 to -10 pp):**
1. Strong negative momentum: -20% decline over 2 weeks with multiple 4-5% down days suggests selling pressure not exhausted. Technical indicators show breakdown.
2. Institutional selling: Large block sales indicate informed money exiting.
3. Recent pattern: 3 of last 4 trading days before Feb 7 were down significantly.

**Upward pressures (+5 to +8 pp):**
1. Earnings catalyst: Company has beaten estimates 3 of last 4 quarters. Q3 showed strong ARR growth ($2.31B record) and raised guidance. Analysts expect $0.96 EPS vs strong historical beat rate.
2. Oversold condition: -20% in 2 weeks may have created short-term bottom, especially if earnings beat.
3. Buyback program: $1B authorization could provide support.

**Net assessment:**
The negative momentum is strong and recent, but the earnings catalyst on Feb 10 is the dominant factor. Historical data shows TRMB beats estimates frequently (75% rate). If earnings beat, the stock could easily rally 5-8% from $66, putting Feb 14 close above Feb 7. If earnings miss, further decline likely.

Given:
- Base rate: 53%
- Strong negative momentum: -8 pp
- Earnings beat probability (~65-70%) with typical +5-7% reaction: +6 pp
- Oversold bounce potential: +2 pp

**Net adjustment: 53% - 8% + 6% + 2% = 53%**

The opposing forces largely cancel out. However, the earnings volatility increases uncertainty. The realized outcome will likely be either significantly up (if beat) or significantly down (if miss), rather than a small move.

Probability calibration:

My outside view base rate of 53% assumed no major catalysts. The presence of earnings on Feb 10 fundamentally alters the distribution - this is no longer a "typical" 5-day period.

Key calibration considerations:
1. If TRMB beats earnings (65-70% probability based on history), expect +5-8% move → Feb 14 close almost certainly above Feb 7
2. If TRMB misses earnings (30-35% probability), expect -5-10% move → Feb 14 close likely below Feb 7
3. Small chance (~5%) of muted reaction

Expected probability calculation:
- P(beat) × P(up|beat) + P(miss) × P(up|miss)
- 0.68 × 0.90 + 0.32 × 0.20 = 0.612 + 0.064 = 67.6%

However, the strong recent negative momentum and institutional selling suggest market may be pricing in a miss or weak guidance. This warrants reducing the beat probability from historical 75% to ~60-65%.

Revised calculation:
- 0.62 × 0.88 + 0.38 × 0.18 = 0.546 + 0.068 = 61.4%

The 90:10 odds implied by 90% seem too confident given execution risk. The 61% figure (roughly 3:2 odds) better reflects the uncertainty around earnings while acknowledging the historical beat rate and oversold technical condition.

Checklist:

1. **Paraphrase**: Will TRMB close on Feb 14, 2026 above its Feb 7, 2026 close? 5 trading days, earnings on Feb 10 mid-window.

2. **Base rate**: 53% for typical 5-day TRMB returns. Current circumstances differ significantly due to earnings catalyst and recent -20% decline, justifying departure.

3. **Consistency**: "61 out of 100 times, TRMB closes higher on Feb 14 than Feb 7." This reflects slight better-than-even odds driven by historical earnings beat rate partially offset by negative momentum.

4. **Key evidence**:
   - TRMB has beaten earnings 3 of last 4 quarters (factual, high quality)
   - Recent 20% decline over 2 weeks with multiple 4-5% down days (factual, high quality)
   - Earnings scheduled Feb 10, mid-window (factual, high quality)
   - Analyst consensus strongly bullish with $96-98 targets (identifiable sources, moderate quality)
   - Institutional selling pressure evident in early Feb (factual, moderate quality)

5. **Blind-spot**: Earnings guidance disappointment. If TRMB beats Q4 but issues weak 2026 guidance, stock could drop 8-12% despite the beat, making my 61% forecast look silly. This scenario has ~15-20% probability and would flip outcome to down.

6. **Status quo**: The recent trend is strongly down (-20% in 2 weeks). However, earnings catalysts often reverse trends. Given high volatility period, status quo extrapolation (continued decline) conflicts with mean reversion and earnings beat potential. The 61% represents a balanced view rather than pure momentum extrapolation.

Probability: 61%